BioMethods Boston.

Robert Langer of MIT, named by Forbes’ magazine among the 25 most significant people in biotechnology, as well as Dr. James Burns, SVP, Medication & Biomaterial R&D at Genzyme Corp., Dr. Donald Ingber, Director, Wyss Institute for Biologically Motivated Engineering at Harvard, Dr. Joachim Kohn, Director, New Jersey Middle for Biomaterials at Rutgers, Dr. Mehmet Toner, Director, BioMEMS Resource Middle at MGH, Dr. Kyongbum Lee, Department Chair, Chemical substance & Biological Engineering at Tufts, and Dr. Mahendra Rao, VP, Stem Cells & Regenerative Medicine at Invitrogen/Lifestyle Technologies – – among many others..Our findings open up a new window in to the normal and diseased brain by providing the first proof that DNA variation in individual neurons could be linked to brain function and Alzheimer's disease, said Jerold Chun, professor in TSRI and its Dorris Neuroscience Center and senior author of the new research. A Devastating Disease of Unknown Trigger Alzheimer's disease is an irreversible brain disease that tends to strike older people. The U.S. Centers for Disease Prevention and Control estimates 5.3 million Americans currently have Alzheimer's disease, and that number is likely to double by 2050 while the population ages. Scientists still have no idea what triggers the majority of Alzheimer's cases, making it difficult to develop a treatment.